Report looks at possible impediments to growth in the specialty market, including patient access.
A new report states that unintended consequences in the specialty drug market may cause the rapid growth in this field to start leveling off.
The QuintilesIMS report-“Specialty Brands: The Pharmaceutical Industry’s Salvation, or Impediments to Future Innovation?”-examines how specialty brands might be an impediment to growth. Innovative specialty drugs carry high price tags, wrote author William McClellan. “[I]nnovation-more precisely its price tag-captures the attention of payers and is forcing them to aggressively manage their budgets in ways that are dampening revenues for specialty brand manufacturers.”
Payers are driving down costs through contract negotiations and by aggressively managing patients’ access to these drugs, the report notes.
Among the other findings of the report: